Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,190 JPY | -0.47% | +0.79% | -2.45% |
04-25 | Hidehiro Imatsu named president of Goldman Sachs Japan | RE |
03-21 | Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. | CI |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The stock, which is currently worth 2024 to 0.5 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company benefits from high valuations in earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.45% | 719M | - | ||
+33.25% | 704B | C+ | ||
+28.59% | 577B | B | ||
-3.55% | 348B | C+ | ||
+18.16% | 327B | B- | ||
+4.36% | 288B | C+ | ||
+14.81% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-3.69% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4534 Stock
- Ratings Mochida Pharmaceutical Co., Ltd.